[{"id":"ee6272e6-f952-43d3-a46c-9401133eded9","acronym":"","url":"https://clinicaltrials.gov/study/NCT07007312","created_at":"2025-06-07T14:39:25.624Z","updated_at":"2025-06-07T14:39:25.624Z","phase":"Phase 3","brief_title":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","source_id_and_acronym":"NCT07007312","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" NPM1","pipe":"","alterations":" ","tags":["NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • daunorubicin • Komzifti (ziftomenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 1300","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 11/01/2031","primary_completion_date":" 11/01/2031","study_txt":" Completion: 11/01/2031","study_completion_date":" 11/01/2031","last_update_posted":"2025-06-05"},{"id":"e17de7f3-6ed2-44ac-8c1d-acf78b25a29e","acronym":"NCI-2017-02296","url":"https://clinicaltrials.gov/study/NCT03375307","created_at":"2021-01-18T16:39:30.359Z","updated_at":"2025-02-25T13:39:36.028Z","phase":"Phase 2","brief_title":"Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes","source_id_and_acronym":"NCT03375307 - NCI-2017-02296","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC","pipe":" | ","alterations":" FANCG mutation","tags":["TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FANCG mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/03/2020","start_date":" 11/03/2020","primary_txt":" Primary completion: 12/16/2025","primary_completion_date":" 12/16/2025","study_txt":" Completion: 12/16/2025","study_completion_date":" 12/16/2025","last_update_posted":"2025-02-21"},{"id":"a2748e44-3f76-4ef4-9c24-1b7476039a69","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554393","created_at":"2022-09-26T14:56:10.693Z","updated_at":"2025-02-25T13:49:33.606Z","phase":"Phase 2","brief_title":"Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)","source_id_and_acronym":"NCT05554393","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation","tags":["TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 09/13/2024","start_date":" 09/13/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-20"},{"id":"c2fb4b7e-7e4c-490d-87bd-2814f4996b26","acronym":"","url":"https://clinicaltrials.gov/study/NCT05886049","created_at":"2023-06-02T14:06:05.454Z","updated_at":"2025-02-25T13:55:14.969Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene","source_id_and_acronym":"NCT05886049","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3 • NPM1 • KMT2A","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • MLL mutation","tags":["FLT3 • NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e daunorubicin • Revuforj (revumenib) • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 06/20/2024","start_date":" 06/20/2024","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-20"},{"id":"2215a379-2b74-4e43-b073-534f2995d428","acronym":"","url":"https://clinicaltrials.gov/study/NCT06001788","created_at":"2023-08-21T14:08:48.344Z","updated_at":"2025-02-25T15:13:42.778Z","phase":"Phase 1","brief_title":"Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT06001788","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" FLT3 • NPM1 • KMT2A","pipe":" | ","alterations":" FLT3 mutation • NPM1 mutation • KMT2A rearrangement • KMT2A mutation • MLL mutation","tags":["FLT3 • NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • NPM1 mutation • KMT2A rearrangement • KMT2A mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • idarubicin hydrochloride • Komzifti (ziftomenib) • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 02/22/2024","start_date":" 02/22/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-13"},{"id":"f18181fc-ba3a-410b-9369-091830924976","acronym":"","url":"https://clinicaltrials.gov/study/NCT05457556","created_at":"2022-09-07T16:55:34.255Z","updated_at":"2025-02-25T15:12:56.234Z","phase":"Phase 3","brief_title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT05457556","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • methotrexate • melphalan • Truxima (rituximab-abbs) • fludarabine IV • thiotepa • busulfan • Mabtas (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 435","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-13"},{"id":"0d9ce0fd-f1c5-49a0-8195-840b50eca958","acronym":"MT2015-29","url":"https://clinicaltrials.gov/study/NCT03314974","created_at":"2021-01-18T16:22:16.872Z","updated_at":"2025-02-25T16:52:01.168Z","phase":"Phase 2","brief_title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","source_id_and_acronym":"NCT03314974 - MT2015-29","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement","tags":["NPM1 • KMT2A • IKZF1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2026","study_completion_date":" 06/10/2026","last_update_posted":"2025-02-04"},{"id":"5e2744aa-d058-4f2c-9e4b-018ea0717e10","acronym":"CR108998","url":"https://clinicaltrials.gov/study/NCT04811560","created_at":"2021-03-23T11:52:16.121Z","updated_at":"2025-02-25T17:00:59.336Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia","source_id_and_acronym":"NCT04811560 - CR108998","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" NPM1 • KMT2A","pipe":"","alterations":" ","tags":["NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bleximenib (JNJ-6617)"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 05/19/2021","start_date":" 05/19/2021","primary_txt":" Primary completion: 02/16/2026","primary_completion_date":" 02/16/2026","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2025-02-03"},{"id":"6dba0cab-3f80-43f0-8cb0-96232c700c74","acronym":"","url":"https://clinicaltrials.gov/study/NCT05521087","created_at":"2022-08-30T20:55:55.553Z","updated_at":"2025-02-25T17:02:06.364Z","phase":"Phase 1","brief_title":"A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias","source_id_and_acronym":"NCT05521087","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" NPM1 • KMT2A • NUP98 • NUP214","pipe":"","alterations":" ","tags":["NPM1 • KMT2A • NUP98 • NUP214"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • vincristine • Oncaspar liquid (pegaspargase) • fludarabine IV • bleximenib (JNJ-6617)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/26/2025","start_date":" 12/26/2025","primary_txt":" Primary completion: 09/11/2026","primary_completion_date":" 09/11/2026","study_txt":" Completion: 01/29/2030","study_completion_date":" 01/29/2030","last_update_posted":"2025-02-03"},{"id":"a188d51f-518e-489f-ab1d-5187bf693db5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05918913","created_at":"2023-06-26T14:09:16.870Z","updated_at":"2025-02-25T15:45:09.016Z","phase":"","brief_title":"Expanded Access Program for Revumenib","source_id_and_acronym":"NCT05918913","lead_sponsor":"Syndax Pharmaceuticals","biomarkers":" NPM1 • NUP98","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1 • NUP98"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Revuforj (revumenib)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-01-10"},{"id":"ed5105cc-c09f-44e6-909c-68846cffde3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06652438","created_at":"2025-02-26T15:12:55.434Z","updated_at":"2025-02-26T15:12:55.434Z","phase":"Phase 3","brief_title":"Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML","source_id_and_acronym":"NCT06652438","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" NPM1","pipe":" | ","alterations":" NPM1 mutation","tags":["NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Revuforj (revumenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 415","initiation":"Initiation: 02/13/2025","start_date":" 02/13/2025","primary_txt":" Primary completion: 05/13/2028","primary_completion_date":" 05/13/2028","study_txt":" Completion: 05/31/2031","study_completion_date":" 05/31/2031","last_update_posted":"2024-10-30"},{"id":"0ab65d95-a746-4376-a36a-807e4d1f1ece","acronym":"HBO-UBC","url":"https://clinicaltrials.gov/study/NCT03739502","created_at":"2021-01-18T18:18:53.880Z","updated_at":"2025-02-25T14:15:15.599Z","phase":"Phase 2","brief_title":"A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant","source_id_and_acronym":"NCT03739502 - HBO-UBC","lead_sponsor":"University of Rochester","biomarkers":" FLT3 • ABL1 • BCR • NPM1 • CD22 • CD34 • CD79A","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation","tags":["FLT3 • ABL1 • BCR • NPM1 • CD22 • CD34 • CD79A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 02/28/2019","start_date":" 02/28/2019","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-08-19"},{"id":"3102105e-b831-48d9-b839-01e75ece3f9a","acronym":"COVALENT-103","url":"https://clinicaltrials.gov/study/NCT05918692","created_at":"2023-06-26T14:09:14.079Z","updated_at":"2024-07-02T16:35:00.712Z","phase":"Phase 1","brief_title":"A Phase 1, Study of BMF-500 in Adults With Acute Leukemia","source_id_and_acronym":"NCT05918692 - COVALENT-103","lead_sponsor":"Biomea Fusion Inc.","biomarkers":" FLT3 • NPM1","pipe":" | ","alterations":" FLT3 mutation • NPM1 mutation • FLT3 wild-type","tags":["FLT3 • NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • NPM1 mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BMF-500"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 07/26/2023","start_date":" 07/26/2023","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-05-27"},{"id":"fb6439e5-b767-47e6-9fe0-4ee26349fda0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05453903","created_at":"2022-07-12T10:54:42.198Z","updated_at":"2024-07-02T16:35:01.650Z","phase":"Phase 1","brief_title":"A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies","source_id_and_acronym":"NCT05453903","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" NPM1 • KMT2A","pipe":"","alterations":" ","tags":["NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • idarubicin hydrochloride • bleximenib (JNJ-6617)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 10/04/2022","start_date":" 10/04/2022","primary_txt":" Primary completion: 05/15/2024","primary_completion_date":" 05/15/2024","study_txt":" Completion: 03/05/2026","study_completion_date":" 03/05/2026","last_update_posted":"2024-05-23"},{"id":"c62a7f73-b1c2-406a-b3bd-f74ccdc4bd18","acronym":"KOMET-007","url":"https://clinicaltrials.gov/study/NCT05735184","created_at":"2023-02-21T16:01:44.880Z","updated_at":"2024-07-02T16:35:03.357Z","phase":"Phase 1","brief_title":"A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML","source_id_and_acronym":"NCT05735184 - KOMET-007","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" NPM1 • KMT2A","pipe":" | ","alterations":" NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation","tags":["NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • daunorubicin • Komzifti (ziftomenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 212","initiation":"Initiation: 07/18/2023","start_date":" 07/18/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-05-16"},{"id":"9c213731-a632-4c0f-8af9-a477196f1cb5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05805605","created_at":"2023-04-10T14:03:04.592Z","updated_at":"2024-07-02T16:35:05.582Z","phase":"Phase 2","brief_title":"Allo HSCT Using RIC and PTCy for Hematological Diseases","source_id_and_acronym":"NCT05805605","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation","tags":["NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 10/22/2027","primary_completion_date":" 10/22/2027","study_txt":" Completion: 10/22/2028","study_completion_date":" 10/22/2028","last_update_posted":"2024-05-07"},{"id":"4709cf4b-f7f6-4c8f-8b77-5a8ac8771021","acronym":"","url":"https://clinicaltrials.gov/study/NCT03674411","created_at":"2021-01-18T18:01:23.529Z","updated_at":"2024-07-02T16:35:10.273Z","phase":"Phase 2","brief_title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","source_id_and_acronym":"NCT03674411","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type","tags":["FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclophosphamide intravenous • spanlecortemlocel (MGTA-456)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 01/02/2019","start_date":" 01/02/2019","primary_txt":" Primary completion: 06/23/2020","primary_completion_date":" 06/23/2020","study_txt":" Completion: 06/28/2024","study_completion_date":" 06/28/2024","last_update_posted":"2024-04-10"},{"id":"fe2e9c02-b568-4273-9f6b-89146f4af44d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02756962","created_at":"2021-01-18T13:30:57.647Z","updated_at":"2024-07-02T16:35:12.037Z","phase":"Phase 2","brief_title":"Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance","source_id_and_acronym":"NCT02756962","lead_sponsor":"Washington University School of Medicine","biomarkers":" FLT3 • NPM1 • CEBPA","pipe":" | ","alterations":" FLT3-ITD mutation • NPM1 mutation • CEBPA mutation","tags":["FLT3 • NPM1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • NPM1 mutation • CEBPA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 07/06/2016","start_date":" 07/06/2016","primary_txt":" Primary completion: 07/31/2033","primary_completion_date":" 07/31/2033","study_txt":" Completion: 07/31/2033","study_completion_date":" 07/31/2033","last_update_posted":"2024-04-02"},{"id":"6920805f-47cc-46c1-9b7c-1cf720663501","acronym":"KOMET-001","url":"https://clinicaltrials.gov/study/NCT04067336","created_at":"2021-01-17T17:22:51.063Z","updated_at":"2024-07-02T16:35:14.761Z","phase":"Phase 1/2","brief_title":"First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04067336 - KOMET-001","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" NPM1 • KMT2A","pipe":" | ","alterations":" NPM1 mutation • KMT2A rearrangement","tags":["NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • KMT2A rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Komzifti (ziftomenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 199","initiation":"Initiation: 09/12/2019","start_date":" 09/12/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-03-15"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"8a9ebf00-3ead-4be6-b6da-08e24836e50c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05011422","created_at":"2021-08-18T14:53:38.899Z","updated_at":"2024-07-02T16:35:15.459Z","phase":"Phase 1","brief_title":"Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies","source_id_and_acronym":"NCT05011422","lead_sponsor":"Washington University School of Medicine","biomarkers":" FLT3 • NPM1 • RUNX1 • KMT2A • ETV6 • CD38 • CREBBP • NUP98 • AFF1 • HLA-DRB1 • PTPRC • HLA-DQB1 • MECOM • NCAM1 • NUP214 • TCF3 • FUS • HLA-B • KAT6A • DEK • AFDN • EGR1 • MLLT10","pipe":" | ","alterations":" MLL rearrangement • NUP98 rearrangement","tags":["FLT3 • NPM1 • RUNX1 • KMT2A • ETV6 • CD38 • CREBBP • NUP98 • AFF1 • HLA-DRB1 • PTPRC • HLA-DQB1 • MECOM • NCAM1 • NUP214 • TCF3 • FUS • HLA-B • KAT6A • DEK • AFDN • EGR1 • MLLT10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • NUP98 rearrangement"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 11/03/2022","start_date":" 11/03/2022","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-03-11"},{"id":"060978f0-6c08-4b4e-a159-a87c4c150dc6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03494569","created_at":"2021-01-18T17:12:30.135Z","updated_at":"2024-07-02T16:35:18.250Z","phase":"Phase 1","brief_title":"Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT03494569","lead_sponsor":"City of Hope Medical Center","biomarkers":" FLT3 • NPM1 • HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" MLL rearrangement","tags":["FLT3 • NPM1 • HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 07/06/2018","start_date":" 07/06/2018","primary_txt":" Primary completion: 11/11/2028","primary_completion_date":" 11/11/2028","study_txt":" Completion: 11/11/2028","study_completion_date":" 11/11/2028","last_update_posted":"2024-02-22"},{"id":"6c05718b-8a7f-4a20-bf78-b51f8a8735e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06052813","created_at":"2023-09-25T14:10:32.555Z","updated_at":"2024-07-02T16:35:18.364Z","phase":"Phase 1/2","brief_title":"A Study of BN104 in the Treatment of Acute Leukemia","source_id_and_acronym":"NCT06052813","lead_sponsor":"BioNova Pharmaceuticals (Shanghai) LTD.","biomarkers":" NPM1 • KMT2A","pipe":" | ","alterations":" NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation","tags":["NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/16/2023","start_date":" 09/16/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-02-21"},{"id":"b62639b3-3bfc-4f4f-81ac-2892933d901a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05115630","created_at":"2021-11-10T14:13:02.708Z","updated_at":"2024-07-02T16:35:19.132Z","phase":"Phase 1/2","brief_title":"Off-the-shelf NK Cells + SCT for Myeloid Malignancies","source_id_and_acronym":"NCT05115630","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • FLT3 • ABL1 • BCR • NPM1 • RUNX1 • ASXL1 • KMT2A • MECOM • NUP214 • GATA2 • DEK","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • MLL rearrangement • Chr del(5q) • FLT3 wild-type","tags":["TP53 • FLT3 • ABL1 • BCR • NPM1 • RUNX1 • ASXL1 • KMT2A • MECOM • NUP214 • GATA2 • DEK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • MLL rearrangement • Chr del(5q) • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 04/08/2022","start_date":" 04/08/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-02-16"}]